Indaptus Therapeutics Provides Latest Clinical Trial Update
Topline: In the Phase 1 INDP-D101 study of Decoy20, a single urothelial cancer patient with liver metastases achieved a...
Silexion Selects CRO for Upcoming SIL204 Phase 2/3 Trials
SIL204 delivered up to 97% inhibition in KRAS Q61H pancreatic cancer cells and roughly 90% inhibition in colorectal models,...
Preclinical Data Supports CNM-Au8 for Parkinson’s Disease
In a human neuron model of Parkinson’s disease, CNM-Au8 improved mitochondrial membrane potential and volume while reducing reactive oxygen...
New SIK3 Inhibitor Approved For Autoimmune Disease Trial
Belgium has approved a first‑in‑human study of Onco3R Therapeutics’ SIK3‑selective inhibitor O3R‑5671, clearing a single‑ and multiple‑ascending dose trial...
New Meta-Analysis: GeneSight Test Improves Depression Outcomes
Across six prospective controlled studies totaling 3,532 adults with major depressive disorder and at least one prior treatment failure,...
Roivant Unveils Remarkable Graves’ Disease Remission Data
In a small proof-of-concept study of uncontrolled Graves’ disease, approximately 80% (17/21) of patients who completed a six-month off-treatment...
Successful ART27.13 Phase 2 Data Soars Partnering Outlook
Interim data from the Phase 2 CAReS trial reported improvements in body weight, lean body mass, and activity among...
Successful EndoQuest Paradigm Trial Procedure at AdventHealth
EndoQuest’s multicenter PARADIGM trial has moved beyond its first site, with AdventHealth Orlando completing its first colorectal endoscopic submucosal...
Artelo’s Cancer Drug Shows Promise in Phase 2 CARES Trial
Artelo’s interim Phase 2 readout in cancer anorexia-cachexia syndrome (CACS) shows patients titrated to 1300 micrograms of ART27.13 gained...
Ascendis to Share New Rare Disease Endocrinology Data
Ascendis is set to present 52-week pivotal data linking improvements in lower extremity alignment to gains in physical functioning...